Compare NOVT & BCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOVT | BCPC |
|---|---|---|
| Founded | 1968 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Major Chemicals |
| Sector | Miscellaneous | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.6B |
| IPO Year | 1999 | 1995 |
| Metric | NOVT | BCPC |
|---|---|---|
| Price | $127.64 | $161.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $144.00 | ★ $176.00 |
| AVG Volume (30 Days) | ★ 286.8K | 175.0K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | N/A | ★ 20.87 |
| EPS | ★ 1.47 | 1.25 |
| Revenue | $521,290,000.00 | ★ $799,023,000.00 |
| Revenue This Year | $8.61 | $8.47 |
| Revenue Next Year | $6.57 | $4.89 |
| P/E Ratio | $88.46 | ★ $34.24 |
| Revenue Growth | ★ 35.49 | 13.56 |
| 52 Week Low | $98.27 | $139.17 |
| 52 Week High | $149.95 | $183.90 |
| Indicator | NOVT | BCPC |
|---|---|---|
| Relative Strength Index (RSI) | 52.27 | 32.95 |
| Support Level | $111.73 | $160.21 |
| Resistance Level | $129.50 | $166.47 |
| Average True Range (ATR) | 5.23 | 4.54 |
| MACD | -0.11 | -1.50 |
| Stochastic Oscillator | 48.79 | 20.49 |
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.